Objective: To determine whether the addition of liraglutide to insulin to treat patients with type 1 diabetes leads to an improvement in glycemic control and diminish glycemic variability. Subjects and methods: In this study, 14 patients with well-controlled type 1 diabetes on continuous glucose monitoring and intensive insulin therapy were treated with liraglutide for 1 week. Of the 14 patients, eight continued therapy for 24 weeks. Results: In all the 14 patients, mean fasting and mean weekly glucose concentrations significantly decreased after 1 week from 130G10 to 110G8 mg/dl (P!0.01) and from 137.5G20 to 115G12 mg/dl (P!0.01) respectively. Glycemic excursions significantly improved at 1 week. The mean S.D. of glucose concentrations decreased from 56G10 to 26G6 mg/dl (P!0.01) and the coefficient of variation decreased from 39.6G10 to 22.6G7 (P!0.01). There was a concomitant fall in the basal insulin from 24.5G6 to 16.5G6 units (P!0.01) and bolus insulin from 22.5G4 to 15.5G4 units (P!0.01). In patients who continued therapy with liraglutide for 24 weeks, mean fasting, mean weekly glucose concentrations, glycemic excursions, and basal and bolus insulin dose also significantly decreased (P!0.01). HbA1c decreased significantly at 24 weeks from 6.5 to 6.1% (PZ0.02), as did the body weight by 4.5G1.5 kg (PZ0.02). Conclusion: Liraglutide treatment provides an additional strategy for improving glycemic control in type 1 diabetes. It also leads to weight loss.

No abstract

No abstract